Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists. 2008

Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.

SCH 58261 is a reported adenosine A(2A) receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A(2A) receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 microM at physiological pH.

UI MeSH Term Description Entries
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
July 2008, Bioorganic & medicinal chemistry letters,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
February 1996, The Journal of pharmacology and experimental therapeutics,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
April 1998, The Journal of pharmacology and experimental therapeutics,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
June 1997, Archiv der Pharmazie,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
March 1998, Journal of neurochemistry,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
April 1998, British journal of pharmacology,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
June 1997, British journal of pharmacology,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
January 1999, Naunyn-Schmiedeberg's archives of pharmacology,
Unmesh Shah, and Claire M Lankin, and Craig D Boyle, and Samuel Chackalamannil, and William J Greenlee, and Bernard R Neustadt, and Mary E Cohen-Williams, and Guy A Higgins, and Kwokei Ng, and Geoffrey B Varty, and Hongtao Zhang, and Jean E Lachowicz
December 2022, Chemical biology & drug design,
Copied contents to your clipboard!